Registry to explore characteristics, use and management of new oral anticoagulants (NOAC) and vitamin K antagonists (VKA) treatment among patients with atrial fibrillation (AF) and recent cerebrovascular disease in a "real-world" setting at a stroke centre.
Registry to explore characteristics, use and management of new oral anticoagulants (NOAC) and vitamin K antagonists (VKA) treatment among patients with atrial fibrillation (AF) and recent cerebrovascular disease in a "real-world" setting at a stroke centre. Special interest is payed to conditions not or only in part investigated in the large randomised controlled Trials (RCT) and that are specific to patients with cerebrovascular disease. This includes early start of NOAC treatment after recent stroke, very old patients, multimorbidity, patients with a history of intracranial haemorrhage (ICH) and patient satisfaction and preferences with VKA/NOACS.
Study Type
OBSERVATIONAL
Enrollment
1,023
treatment with NOACs or VKAs initiated or continued for prevention of ischemic events
Felix Platter Spital
Basel, Switzerland
Dep. of Neurology, Hospital of the University of Basel
Basel, Switzerland
Change in anticoagulation (NOAC and VKA) treatment
assessment of details of NOAC or VKA application (start, pause, dosage)
Time frame: time from index event (= cerebrovascular event) to Follow- up assessments at 3-, 6-, 12- and 24 months after index event
Change in glomerular filtration rate (GFR)
impact of kidney function (in particular volatile GFR (ml/min) around the threshold for reduced dosage)
Time frame: time from index event (= cerebrovascular event) to Follow- up assessments at 3-, 6-, 12- and 24 months after index event
Drug adherence for anticoagulation (VKA) treatment
monitor the frequency of VKA use in patients with stroke or TIA attributable to AF, (a) among patients without pre-existing anticoagulation, (b) among patients under insufficient VKA therapy, and (c) among patients with sufficient VKA therapy, assessed by telephone or clinical visit
Time frame: time from index event (= cerebrovascular event) to Follow- up assessments at 3-, 6-, 12- and 24 months after index event
Change in anticoagulant treatment
If anticoagulant treatment was stopped or switched to any other drug (NOAC/VKA), reason for switching will be documented
Time frame: time from index event (= cerebrovascular event) to Follow- up assessments at 3-, 6-, 12- and 24 months after index event
Recording of Adverse Events (AE)
Causality for AE will be assessed as related, possibly related or non-related to the prescribed anticoagulant
Time frame: time from index event (= cerebrovascular event) to Follow- up assessments at 3-, 6-, 12- and 24 months after index event
Change in modified Rankin Scale (mRS)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability; scale runs from 0-6, running from perfect health (=0) without symptoms to death (=6)
Time frame: time from index event (= cerebrovascular event) to Follow- up assessments at 3-, 6-, 12- and 24 months after index event
Co-morbidities
Recording of co-morbidities
Time frame: time from index event (= cerebrovascular event) to Follow- up assessments at 3-, 6-, 12- and 24 months after index event
Drug adherence for anticoagulation (NOAC) treatment
monitor the frequency of NOAC use in patients with stroke or TIA attributable to AF, assessed by telephone or clinical visit
Time frame: time from index event (= cerebrovascular event) to Follow- up assessments at 3-, 6-, 12- and 24 months after index event